Early Life Risk Factors for Asthma at Early Adulthood
David Peloza, MD, Michael D. Evans, M.S., Ronald E. Gangnon, PhD, James E. Gern, MD FAAAAI, Robert F. Lemanske, Jr, MD, FAAAAI, and Daniel J. Jackson, MD FAAAAI; University of Wisconsin-Madison, Madison, WI. RATIONALE: We aimed to identify relationships among early life risk factors such as viral illnesses and aeroallergen sensitization and the persistence of asthma to early adulthood. METHODS: 180 newborns at high-risk based upon parental histories of asthma and/or allergy were enrolled at birth in the Childhood Origins of Asthma (COAST) study and followed prospectively to 17-18 years of age. Current asthma was diagnosed based on physician diagnosis of asthma, medication use and symptoms in the prior year. The associations between early life risk factors and asthma at age 17-18 years were assessed by logistic regression. RESULTS: Passive smoke exposure (OR 5 2.7, 95% CI 1.4-5.5, p50.005) and sensitization to aeroallergen(s) (OR 5 6.4, 95% CI 2.3-18, p50.0003) or food (OR 5 4.1, 95% CI 2.0-8.4, p5<0.0001) at 1 year of age were associated with significantly increased risk for asthma at 17-18 years of age. Wheezing illnesses with rhinovirus (RV) (OR 5 2.9, 95% CI 1.5-5.5, p50.001) and respiratory syncytial virus (RSV) (OR 5 2.4, 95% CI 1.2-4.7, p50.01) in the first 3 years of life were also associated with increased risk of asthma. CONCLUSIONS: In the high-risk COAST birth cohort, early life environmental tobacco smoke exposure, RV and RSV-induced wheezing, and sensitization to both aeroallergens and food were all associated with increased risk for asthma persistence to early adulthood. Traditionally IV immunoglobulin (IVIG) is administered to prevent infections but may suppress autoimmune features. Anecdotal reports suggest autoimmune control may be achieved with subcutaneous immunoglobulin (SCIG). This study aims to evaluate immunoglobulin replacement route trends amongst CVID patients listed on the USIDNet registry. METHODS: A query to the USIDNet registry resulted in 387 CVID patients with a history of autoimmunity (CVID-A) and 399 CVID patients without autoimmunity (CVID-NA). Replacement modality was compared. Additional variables assessed included sex, family history, specific autoimmune disorder and adjunctive immunomodulatory medications. Statistics were performed using GraphPadv.7 and STATAv.15. RESULTS: A significant difference in replacement between CVID-A and CVID-NA was noted (p<.0001) with more CVID-A patients using SC therapy. The odds of having CVID-NA were 3.14 times higher for patients using IVIG (p<0.001 95% CI [2.19, 4.49]). In the autoimmune population, 67.3% were maintained on SC; 27.7% had at least one cytopenia; 28.7% had at least one gastrointestinal diagnosis. There were no significant differences in modality use in patients with a history of autoimmune cytopenias (p5.396), endocrinologic (p5.108) or dermatologic disorders (p5.540). Autoimmune hepatitis, celiac or inflammatory bowel disease cases were more likely to receive IVIG (p5.0297). CONCLUSIONS: CVID-NA patients were more likely to use IVIG compared to CVID-A patients. Our data suggest against the notion that IVIG outperforms SC therapy in patients with a history autoimmunity. Given the limitations of database analysis, institutional-level, prospective data is required to identify characteristics predictive of success on SCIG.
B cell Activation in Specific Polysaccharide Antibody Deficiency
Stephen J. McGeady, MD FAAAAI; A I duPont Hosp. for Children, Wilmington, DE. RATIONALE: It is unknown whether the defect in patients with specific antibody deficiency deficiency (SAD) is a single one or if this is a heterogeneous population with multiple defects. Determining B cell activation by a variety of stimuli might address that unknown. METHODS: Peripheral blood B cells of 4 patients with SAD who produced antibody to protein but not polysaccharide antigens, 2 with common variable immunodeficiency (CVID) and 4 normal controls were studied. Lymphocytes were separated from heparinized whole blood by density gradient centrifugation, and mature B cells (CD 20+, CD 27-,CD10-) were stimulated with anti-B cell receptor (Fab'2 anti IgM,G) in a range of doses, ligation of toll like receptor (TLR)2 by PAM 2 cys K4 and of TLR7/8 by ssRNA. B cell activation status was assessed by CD86 (B7-2) expression on flow cytometry. RESULTS: Patients with SAD were heterogeneous. Two were similar to controls in TLR responses but had lower responses to BCR antibody. One had normal BCR response, but reacted poorly to TLR ligands, and one showed greater responses than control to both BCR and TLR stimuli. Patients with CVID had poor responses to both BCR and TLR stimuli, although the TLR responses were greater. CONCLUSIONS: (1) Patients with SAD are heterogeneous in the integrity of their B cell activation pathways, with impaired BCR activation, impaired TLR activation and hyper activation of both pathways being observed. (2) CVID patients were deficient in Cell activation by both pathways, although some activation via TLR was detected.
